NASDAQ · STRO
Sutro Biopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for STRO: Nov 5, 2026
Sutro Biopharma, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.88. The reported EPS for the same quarter last year was $-6.7.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.88 | $-1.40 | $-2.38 | 5 |
| Dec 2026 | $-1.81 | $-1.08 | $-2.46 | 5 |
| Mar 2027 | $-1.85 | $-1.48 | $-2.11 | 4 |
| Jun 2027 | $-1.65 | $-1.21 | $-2.32 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Aug 12, 11:39 AM EDTSutro Announces Encouraging Early Clinical Activity From STRO-004 Phase 1 Study; Stock Down(RTTNews) – Sutro Biopharma, Inc. (STRO), a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs), has reported its second-quarter 2026 financial results and provided pipeline updates, highlighting encouraging early clinical activity from STRO
- Zacks · Aug 11, 8:35 AM EDTUpstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue EstimatesUpstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 8:35 PM EDTBioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue EstimatesBioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · May 28, 8:03 PM EDTBarclays Initiates Coverage of Sutro Biopharma (STRO) with Overweight RecommendationFintel reports that on May 28, 2026, Barclays initiated coverage of Sutro Biopharma (NasdaqGM:STRO) with a Overweight recommendation. Analyst Price Forecast Suggests 14.40% Upside
- Fintel · May 15, 8:04 PM EDTWedbush Upgrades Sutro Biopharma (STRO)Fintel reports that on May 15, 2026, Wedbush upgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Neutral to Outperform. Analyst Price Forecast Suggests 13.40% Downside
- Zacks · May 6, 6:30 PM EDTMannKind (MNKD) Reports Q1 Loss, Misses Revenue EstimatesMannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 5, 10:00 AM EDTOcugen (OCGN) Reports Q1 Loss, Beats Revenue EstimatesOcugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Apr 30, 12:56 PM EDTMizuho Initiates Coverage of Sutro Biopharma (STRO) with Outperform RecommendationFintel reports that on April 30, 2026, Mizuho initiated coverage of Sutro Biopharma (NasdaqGM:STRO) with a Outperform recommendation. Analyst Price Forecast Suggests 9.37% Downside
- RTTNews · Apr 20, 2:21 AM EDTSutro Biopharma Presents Promising Preclinical Data For Pipeline ADC Programs At AACR 2026(RTTNews) – Sutro Biopharma, Inc. (STRO), a clinical-stage biotechnology company, announced promising preclinical data across its pipeline of next-generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.
- RTTNews · Apr 9, 6:06 AM EDTRLAY Hits 52-Week High, MPLT Nears Lockup Expiry; ORKA Makes EVERLASTing Gains(RTTNews) – The following are some of the biotech stocks that hit new 52-week highs on April 8, 2026.
- Zacks · Apr 8, 8:31 AM EDTSutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Fintel · Apr 7, 8:04 PM EDTLeerink Partners Initiates Coverage of Sutro Biopharma (STRO) with Outperform RecommendationFintel reports that on April 7, 2026, Leerink Partners initiated coverage of Sutro Biopharma (NasdaqGM:STRO) with a Outperform recommendation. Analyst Price Forecast Suggests 47.13% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Sutro Biopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.